NewAmsterdam Pharma Company (NAMS) Corporate presentation summary

Addressing unmet needs in cardiometabolic diseases

• Obicetrapib and its combination with ezetimibe offer significant LDL-C lowering, with monotherapy reducing LDL-C by 35-40% and combination therapy by ~50% versus placebo, addressing a large population not at LDL-C goal in the US and globally.

• The drug demonstrates favorable safety and tolerability in over 3,500 patients, with blinded safety data in more than 9,500 patients.

• Obicetrapib also lowers Lp(a) by ~45% and shows beneficial effects on other lipid and glycemic markers, with a potential $8 billion+ global peak sales opportunity.

• Comprehensive IP protection extends until mid-2043, supporting long-term commercial potential.

Recent progress and clinical milestones

• Results from three Phase 3 trials (BROOKLYN, BROADWAY, TANDEM) were completed and announced, with publications in NEJM and The Lancet.

• Company size doubled, with new offices in Amsterdam, Miami, and Philadelphia, and commercial/medical teams established.

• Secured $729M in funding by year-end 2025 to support a potential US commercial launch.

• EMA submission and full Alzheimer's data presentation occurred in 2H 2025.

Market opportunity and treatment landscape

• Over 30 million US patients on lipid-lowering therapy are not at LDL-C goal, with 18 million far from goal and 6 million not on statins.

• Non-statin and branded lipid-lowering therapies are experiencing high double-digit growth, with increasing payer willingness to cover appropriately priced medications.

• Less than one-third of high-risk patients achieve LDL-C targets, highlighting the need for more effective therapies.